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Abstract 
Background: Oral cavity squamous cell carcinoma (OCSCC) has been reported to have 
stagnant survival rates over the last generation.  This report represents the first 
population-based study with a rigorous subsite analysis of OCSCC.  Recently, The 
Cancer Genome Atlas (TCGA) released a broad molecular characterization of Head and 
Neck Squamous Cell Carcinoma (HNSCC) – however comparative genomics has not yet 
been performed on individual oral cavity subsites. 
Methods: The Surveillance, Epidemiology, and End Results (SEER) database (1988–
2010) was used to examine 16,298 adult cases of OCSCC.  Trends in tumor subsite, 
staging, patient demographics, treatment characteristics, and survival over time were 
examined.  Subsequently, data from TCGA were used to evaluate mutation, copy 
number, and expression profiles of clinical subgroups of interest identified by 
epidemiological data. 
Results: The overall incidence of OCSCC decreased between 1988 and 2007, but there 
was a marked increase in the incidence oral tongue squamous cell carcinoma (OTSCC).  
There were also trends towards oral tongue (OT) cancers being diagnosed in younger 
individuals and at earlier stages.  Five-year overall survival of OCSCC increased between 
1988 and 2007 (39.9% to 50.4%, p< .01), independent of changes in patient and tumor 
characteristics.  Much of this survival increase was specifically attributable to increases 
in survival of OT cancers.  Multivariate analysis revealed that age, stage, and grade were 
important covariates with survival, but oral subsite was not.  Genomic analyses aimed at 
characterizing OT tumors higher rates of mutation in p53 and CDKN2A, and lower rates 
of mutation in most other genes.  CASP8 mutations were found almost exclusively in 
non-tongue oral subsites.  OT and oral cavity (OC) cancers, even in non-smokers, did not 
show the characteristic molecular changes associated with Human Papillomavirus (HPV) 
-related cancers, but instead closely resembled traditional smoking-related tumors.  
Clustering analysis revealed that OT tumors possess a distinct expression signature. 
Conclusions: Survival for OCSCC has improved significantly over the past 20 years.  
Additionally, OTSCC now has a superior 5-year survival compared to other OC subsites; 
this can be attributed to trends towards earlier staging and younger population.  The 
molecular profile of OTSCC, including tumors occurring in young, non-smokers,  
resemble that of traditional head and neck cancers (related to environmental carcinogens) 
– and is very different from HPV-related oropharyngeal cancers. 
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Introduction 
Epidemiology of Head and Neck Cancer 
Head and neck cancer is the 6th most common malignancy worldwide, a statistic 
commonly quoted in the literature [1].  The vast majority (greater than 90%) of cancer in 
the head and neck is squamous cell carcinoma (SCC), which is the sole focus of this 
investigation.  Squamous cell carcinomas of the head and neck (HNSCC’s), though 
commonly and conveniently classified as a single entity, are actually a heterogeneous 
group of diseases.  Cancers affecting the sinonasal region, for example, are quite different 
in many respects from those affecting the larynx.  However, they are often lumped 
together due to their anatomical proximity, occurrence on mucosal surfaces, and similar 
(but not identical) risk factors.  Nevertheless, even adjacent areas of the aero-digestive 
tract can be affected in drastically different ways by cancer.  Such is the case with 
cancers of the oral cavity and oropharynx. 
Oral Cavity Cancer 
The oral cavity is the most commonly affected site within HNSCC.  In 2012, oral 
cavity cancers accounted for 26,000 new cases and 6,000 deaths in the US [2].  Oral 
cavity squamous cell carcinoma (OCSCC) has been associated with poor and stagnant 
survival, particularly for advanced stage disease [3, 4].  Traditionally, it has been closely 
associated with tobacco and alcohol exposure, and has predominantly affected an older 
population, representing a typical dose-response effect [5-7].  These environmental toxins 
cause direct damage to mucosal surfaces, and possess dozens of carcinogenic 
compounds, such as polycyclic aromatic hydrocarbons (PAH’s), oxidating substances, 
  
and free radicals.  Following activation by endogenous metabolic enzymes (cytochrome 
p450 enzymes), these can form DNA adducts or induce epigenetic changes.  If enough of 
these genetic defects accumulate and affect critical genes over time, carcinogenesis is the 
result.   
Oropharyngeal Cancer and HPV 
In stark contrast to most cancers of the head and neck, cancers of the oropharynx 
(OPSCC) are on a meteoric rise in incidence [8], and affect an entirely different 
population.  This is because greater than 80% of OPSCCs are thought to be caused by the 
human papilloma virus (HPV) [9].Papillomaviruses are sexually transmitted, double 
stranded DNA viruses which infect proliferating keratinocytes in the basal layer of 
epithelial surfaces.  First discovered in cervical cancers, HPV possesses the ability to 
integrate its DNA into the host genome, utilizing host machinery to produce proteins 
which are inherently oncogenic (especially HPV E6 and E7 proteins) due to their 
inhibition of powerful tumor suppressors, Rb and p53, respectively.  In the normal viral 
lifecycle, intracellular viral replication and assembly increases as keratinocytes 
differentiate and mature, ultimately resulting in shedding of infectious particles as 
epithelial cells are sloughed off the outer surfaces of the epithelium.  As would be 
expected, the known risk factors for HPV-related cancers are primarily sexual (number of 
sexual contacts, early initiation of sexual contact, and oral sex) [10, 11].   In addition, the 
cancers that arise in this region tend to affect a younger and predominantly male 
demographic with little exposure to classic risk factors such as tobacco.  They also have 
distinct clinical characteristics, such as their predilection for the oropharynx, tendency for 
  
neck metastasis, better response to chemo-radiotherapy, and overall better prognosis 
([12]). 
The Anatomy of the Oral Cavity and Oropharynx 
The oral cavity and oropharynx are located immediately adjacent to one another, 
working together for the purpose of swallowing, phonation, and other functions.  The oral 
cavity begins anteriorly at the skin-vermilion junction of the lips, and is bound laterally 
by the cheeks.  It extends posteriorly to the boundary of the oropharynx, which is the 
hard-soft palate junction superiorly, and the terminal sulcus (line of the circumvallate 
papillae) on the tongue surface.  Importantly, the adjacent oropharyngeal area includes 
the soft palate, the base of the tongue (the 1/3 of the tongue posterior to the terminal 
sulcus), and the palatine tonsils (Appendix A).  The oral cavity proper can be broken into 
well-defined anatomical subsites, including the mucosal lip anteriorly, the buccal surfaces 
laterally, the hard palate superiorly, the floor of mouth inferiorly, the gingival surfaces, 
the retromolar trigone laterally, and the “oral” tongue (the anterior 2/3 of the tongue) 
(Appendix A).  The clinical relevance of these different subsites is not clear – and they 
are not component of staging or management.  Instead, OCSCC has a single staging 
protocol.  Previous studies examining the prognostic significance of oral subsites, 
especially the oral tongue, have demonstrated conflicting results [13-18].  A significant 
difference between subsites would indicate that subsite should be considered during the 
staging or treating of cancers.  A goal of this study was to clarify whether various oral 
subsites differed in their clinical characteristics or prognosis.   
Oral Tongue Cancer: Evidence of a Changing Disease 
  
The oral tongue is the subsite within the oral cavity responsible for the highest 
number of cancers. Interestingly, it appears the clinical characteristics of oral tongue 
squamous cell carcinoma (OTSCC) have changed over the last few decades [19, 20].  For 
example, the overall rates of HNSCC have steadily declined, due to decreases in tobacco 
and alcohol usage [21].  Over the same period, the incidence of OTSCC is on the rise.  
OTSCCs are also afflicting a greater proportion of non-smokers, women, and a younger 
population [22-25].  Although this shift in the epidemiology of OCSCC raises many 
possible hypotheses, none have been validated.  One of the goals of our investigation was 
to further clarify the characteristics of this trend. 
Based on the distinct differences in etiology and clinical characteristics, a clear 
demarcation between the oral cavity and oropharynx would seem essential.  However, 
many previous database studies examining OCSCC have failed to appropriately 
distinguish it from the oropharynx.  In the SEER database, the “Tongue” site code is 
misleadingly composed mostly (>50%) of cancers which are actually oropharyngeal in 
origin (e.g. the base of tongue and lingual tonsil).  Several previous studies using the 
SEER database have utilized this “Tongue” category to represent oral cavity cancers, 
inadvertently misclassifying a significant proportion of oropharyngeal cancers into their 
data for the oral cavity [26, 27].   
Management of OCSCC has evolved over the past two decades, with efforts 
aimed at early detection, advances in surgical and reconstructive treatments, an increased 
role for adjuvant chemotherapy with radiation, and advances in radiotherapy techniques.  
Additionally, there has been increased standardization of therapy, as well as a trend 
toward more patients being treated in experienced, high-volume academic centers.  Given 
  
these changes, it is important to evaluate our progress in the battle against OCSCC.  
Though some head and neck cancers have traditionally been associated with stagnant 
survival rates[28, 29], recent studies have shown that survival in oral cavity cancers may 
be improving [26, 27, 30].  However, given that many previous studies have 
inadvertently grouped oral cavity cancers with the oropharyngeal cancers, which are 
known to have higher survival rates, it is important to clarify this analysis using 
appropriate anatomical distinctions.  Another aim of this investigation is to determine the 
survival trends related to OCSCC as well as its subsites, and to develop a multivariate 
model to determine the clinical and treatment characteristics which correlate with 
survival. 
One hypothesis addressing the increased incidence and potential improved 
survival of OCSCC is that HPV has become responsible for a proportion of oral tongue 
cancers [26].  Common sense might justify this assertion, given that HPV is known to 
affect mucosa only millimeters away (in the oropharynx), and given that HPV related 
tumors affect a younger population and carry improved prognosis.  However, this has 
apparently not been the case, as HPV has not been detected in a significant number of 
oral cavity cancers [31-33].  Additionally, recent studies examining the genomics of these 
oral tongue tumors have found that they do not carry the characteristic molecular 
trademarks of cancers caused by HPV (such as p16 expression and lack of p53 mutations) 
([34] [9].).    
 
 
  
Specific Aims 
• Aim 1 – Determine if oral cavity subsites vary in their clinical characteristics or 
prognosis and identify important clinical factors correlating with survival.  An 
improved understanding of the typical characteristics and outcomes of oral 
subsites will assist clinicians in treatment decision making and prognostication. 
 
• Aim 2 – Identify changes in survival over time for cancers of the oral cavity/oral 
tongue.  Understanding whether/how this disease is changing and correlating 
changes with changes in diagnostic characteristics and therapeutic approaches 
will provide data to support further studies to accelerate positive correlations.   
 
• Aim 3 – Identify characteristics of the genomic landscape for OTSCC, and 
determine if it is significantly different from other cancers in the oral 
cavity/head and neck.   Identifying molecular characteristics of OTSCC and 
comparing them to those of other oral subsites and HNSCC may provide insight 
into distinctions that correlate with origin, pathogenesis, or identify new targets 
for therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Materials and Methods 
Data Collection 
Data were obtained from the Surveillance, Epidemiology, and End Results (SEER 
- 18 Registry dataset, November 2012) database of the National Cancer Institute. The 
SEER database contains epidemiological information on the incidence and survival of 
cancer in the United States, along with routinely collected clinical information for each 
patient.  The SEER program collects and publishes this data from state-run cancer 
registries covering roughly 28% of the US population, which have been chosen to 
represent the ethnic makeup of the US as a whole.  SEER coverage includes 26% of 
African Americans, 38% of Hispanics, 44% of American Indians and Alaska Natives, 
50% of Asians, and 67% of Hawaiian/Pacific Islanders.  
We carefully selected and categorized oral cavity subsites for analysis by 
topography codes: lip (C00.3-C00.5), tongue (C02.0-C02.3), gum (C03.0-C03.1,C03.9), 
floor of the mouth (C04.0-C04.1,C04.8-C04.9) Hard palate (C05.0), buccal areas (C06.0-
C06.1) and retromolar area (C06.2).  Subsites representing the oropharynx were carefully 
excluded in order to avoid inclusion of oropharyngeal cancers, which are known to have 
different etiology and prognosis.  Subsites excluded were the base of the tongue, uvula, 
soft palate, and lesions of the tongue and mouth that overlap with each of those regions.  
Malignant SCC diagnoses were selected using the histology codes 8050-8089.  We 
included patients 1) with only one primary 2) Diagnosed from 1988-2007 3) age 18 or 
over 4) actively followed. 
Statistical Analysis 
  
Many clinical variables were examined, including patient demographics, tumor 
characteristics, treatment modality, and follow-up data.  All raw data were downloaded 
during a single session, and many of the variables were then categorized into groups 
using custom programs in MATLAB (The MathWorks, Inc., Natick, Massachusetts, 
United States, version 7.8.0).  Demographic variables included gender, year of diagnosis 
(stratified into groups of 1988-92, 1993-97, 1998-02, and 2003-07), age (stratified into 
18-40, 41-55, 56-70, 71-85, 85+), race (recoded into ‘White’, ‘Black’, and ‘Other: 
American Indian/AK Native, Asian/Pacific Islander’). Tumor characteristic variables 
included stage, grade, primary subsite.  Disease stage was classified according to 
American Joint Commission of Cancer (AJCC) 7th edition staging guidelines. T 
classification was derived from measurements of the tumor size and degree of extension 
into adjacent organs. N classification prior to 2004 was determined from a single variable 
encoding lymph node involvement, while N classification from 2004-2010 was derived 
from two variables encoding lymph node size and lymph node involvement.  Though the 
coding schemes changed between these periods, we carefully translated them into N0, 
N1, N2, and N3 classes.  For M classification, metastatic tumors included metastases to 
distant sites.  All T, N, and M classification was performed according to the SEER 
Program Coding and Staging Manual 2010.  Treatment-related variables include 
treatment modality (surgery, radiation, or both), and whether or not neck dissection was 
performed.  Radiation therapy included one or more of the following: external beam 
radiation, radiation implants, radiation NOS, or radioisotopes.  The variable ‘Scope of 
Regional Lymph Node Surgery’ indicated whether and what type of neck dissection was 
performed.  However, this was only available from 1998 and on.  No variable explicitly 
  
indicated the performance of a neck dissection before this, so we used the number of 
lymph nodes which were pathologically examined as a surrogate.  While some lymph 
nodes are processed with a primary tumor specimen, it is quite rare for there to be more 
than a few lymph nodes in the resection of a primary site tumor.  If more than 15 lymph 
nodes were pathologically examined, we used this as a surrogate to indicate that a lymph 
node dissection as performed. We chose this based on personal surgical experience, as 
well as previous published reports [35].  Upon retrospective analysis, this variable was 
found to have a very high rate of concordance with the “Scope of Regional Lymph Node 
Surgery”, suggesting it was a reliable indicator of whether a dissection of the neck was 
performed. 
The year of diagnosis, year of death, and current vital status were used to 
determine two and five year survivals.  Five-Year survival was evaluated by using a 
Kaplan-Meier analyses, and survival of different groups was compared by log rank tests.  
Disease specific survival includes only death attributable to the oral cavity cancer as the 
event of interest.  This helps account for changes in the population’s baseline survival 
and approximates relative survival.  Relative survival calculates the survival of the study 
group in comparison to the baseline survival of the general population matched for age, 
race and sex.  This was calculated using the Ederer II method [36] and found to be 
extremely similar to disease specific survival, and thus not included.  To examine 
changes in the above characteristics over time, the proportions of each attribute were 
tabulated for each time period.  A chi squared test was used to test the significance of 
changes in these characteristics over time.  To further explore the characteristics or oral 
  
tongue cancer, we also performed the analyses described above for each individual 
subsite within the oral cavity. 
A multivariate analysis was conducted using a Cox proportional hazards ratio.  
Using a Cox proportional hazards regression, a univariate analysis was first performed 
for each individual demographic, clinical, and treatment variable in order to determine 
whether each was potentially associated with survival.  The final multivariate “adjusted 
model” included all the covariates deemed to be significantly associated with survival 
when evaluated individually.  Using the Cox proportional hazards regression to create a 
model with all the relevant variable, hazard ratios were determined, and are displayed as 
compared to the reference value (1.00) within each category.  All tests were 2-sided, and 
statistical significance was determined at the p<.05 level.   
A case listing with clinical information for each subject was obtained from the SEER 
database and all statistics were computed using MATLAB Statistics Toolbox.     
Genomic Analysis 
We utilized data available from The Cancer Genome Atlas (TCGA) HNSCC [9] 
project to examine the mutational, copy number variation (CNV), and RNA expression 
profiles of  head and neck cancer specimens.  The TCGA is a collaborative, multi-
institution effort supervised and funded by the National Cancer Institute (NCI)  and the 
National Human Genome Research Institute.  Begun in 2005, the goal was to catalogue 
genetic alterations responsible for different types of cancer.  Raw data is publicly 
available, and can be downloaded through a portal TCGA website.  Clinical data were 
downloaded via the TCGA data matrix and samples were identified a segregated 
according to anatomic subsite, patient age, and smoking status/pack year history.  This 
  
clinical data were used to further divide the sample into subgroups.  The “Oral Tongue” 
group consisted of tumors originating in the oral tongue.  The “Oral Cavity” group 
consisted of tumors originating elsewhere in the oral cavity (FOM, hard palate, buccal 
mucosa, alveolar ridge, lip, other).  The “Oropharynx” (OP) group originated in the 
oropharynx (base of tongue, tonsil, or oropharynx).  The “Larynx/Hypopharynx” (LH) 
group originated at those respective sites.   Within the OT category, we further segregated 
samples based on traditional vs. non-traditional demographics.  The “Young Tongue 
Non-Smoker” (YTN) subgroup was defined as being located in the oral tongue, age <= 
55, and a confirmed history of ‘Lifelong Non-Smoker”.  The more traditional, “Old 
Tongue Smoker” (OTS) subgroup, was defined as located in the oral tongue, age >55, 
and a confirmed history of smoking (minimum 5 pack-years).  After segregating into 
anatomical sub-groups, we analyzed and compared the mutational, copy-number, and 
RNA expression profiles of each group.   
For somatic mutation data, sequencing data were generated by the TCGA on a 
IlluminaGA system. The mutation calls were generated at Broad Institute Genome 
Sequencing Center using the Mutect method.  These calls were then downloaded through 
the UCSC Cancer Genomics Browser[37, 38], and mutational frequencies were 
calculated using MATLAB.  To determine significantly mutated genes for each clinical 
subgroup, level 2 mutational data were downloaded from the TCGA data portal and 
processed using the MutSigCV module within the Broad Institute’s GenePattern portal 
[39, 40].  Significant calls in MutSigCV (based on background mutation rate, expression, 
and mutation types) were recorded for each subgroup and compared to one another. 
  
For copy number analysis, copy number profile was measured experimentally using 
whole genome microarray at a TCGA genome characterization center.  Subsequently, 
GISTIC2 method was applied using the TCGA FIREHOSE pipeline to produce gene-
level copy number estimates.  GISTIC2 estimates are thresholded to estimate values of -
2,-2,0,1,2 representing homozygous deletion, single copy deletion, diploid normal copy, 
low-level copy number amplification, or high-level copy number amplification.  Genes 
were then mapped onto human genome coordinates and visualized using UCSC software 
and tools available through the Cancer Genome Browser [37, 38].  To illustrate the full 
spectrum of CNVs, visual comparison of amplifications/deletions across subgroups was 
performed on the UCSC Cancer Genome Browser, along with student’s t-tests comparing 
the mean value of each copy number locus between the two comparison groups. 
Since CNVs and somatic mutations can have a similar impact on cancer-related genes, 
we performed a combined mutation+CNV analysis to gain an integrated perspective on 
the genes most commonly altered in HNSCC.  This data were obtained/visualized and 
printed through the cbioportal website maintained by Memorial Sloan Kettering Cancer 
Center [41].  Calls for this mutation and copy number data were performed according to 
the TCGA HNSCC project, and genes cited as most commonly indicated were selected 
for analysis [9].  Samples were sorted according to clinical subgroup and genes were 
sorted according to pathway. 
RNA sequencing and expression quantification were performed as previously described 
by TCGA using IlluminaHiSeq2000 [9].   This data, after being normalized across the 
TCGA HNSCC cohort and log-transformed by the UCSC Cancer Browser Team, was 
downloaded for further analysis.  Expression data were segregated according to clinical 
  
subgroup and analyzed using the ComparativeMarkerSelection through the GenePattern 
portal [39, 42].  This compared expression of all genes between the relevant clinical 
groups to select the genes most significantly upregulated or downregulated in a specific 
cohort.  The most significantly up- or down-regulated genes for each cohort was 
recorded, and visualized using the HeatMapViewer through the GenePattern portal [39].  
The list of genes which were up and down-regulated for each subgroup were analyzed for 
enrichment of certain pathways, functions, or components using Gene Ontology and 
Gorilla Enrichment analyses [43, 44].  Since most of the genes found to be upregulated in 
Oral Tongue Cancers vs. others were muscle-related, we also repeated this analysis using 
only known cancer-related genes according to the COSMIC database [45].  Lastly, to 
determine if there were separate subgroups of samples defined by significantly different 
gene expression, unsupervised clustering using Pearson correlation for both samples and 
genes and pairwise average linkage was performed and visualized through the 
HierarchicalClustering tool in the GenePattern portal [39, 46].  We selected those genes 
which were most variably expressed across all samples.   This was performed for 1) the 
full set of HNSCC and 2) Oral Tongue tumors.  The sample clustering was analyzed for 
the degree of clinical subgroup clustering, and significance of the clusters was tested 
using SigClust, though not shown here.  We also performed a separate clustering using an 
‘intrinsic gene list’ utilized by previously published HNSCC clustering studies, which is 
not shown here[9, 47, 48]. 
Results 
Characteristics of OCSCC 
  
From 1988 – 2007, SEER reported a total of 16,298 cases of OCSCC.   Median 
age at diagnosis was 63 years.  The male:female ratio was 1.5:1, and the 
white:black:other ratio was 12.5:1.3:1   
Demographic trends in OCSCC 
When broken into 5 year intervals, patient demographics underwent a small but 
gradual shift over the study period (table 1).  The mean age at diagnosis decreased 
modestly from 64.3 to 63.5 years, and gradually included more middle aged patients (41-
55) and fewer patients aged 56+ (p < .001).  There was also an increase in the proportion 
of female subjects, comprising 35.7% of diagnoses in the first time period, and 39.2% in 
the final time period (p <.001).  The proportional breakdown of affected races remained 
fairly stable over time, with 84.4% of cases affecting whites, 8.1% blacks, and 7.5% 
‘other’ in the final time period.  This represented a slight decline in the proportion of 
black patients from the first time period (9.5% to 8.1%), and an increase in ‘other’ (5.0% 
to 7.5%). 
Incidence Trends of OCSCC and Affected Subsites 
While incidence rates of all other oral cavity subsites have remained stagnant or 
decreased, incidence of oral tongue SCC rose 17% (figure 1).  Oral tongue cancers 
comprised only 30% of all oral cavity cancers in 1988-92, but increased to 38% in 2003-
07 (table 1).  Notably, floor of mouth cancers, initially comprising 34.2% of OCSCC 
diagnoses, dropped to 23.3% between the initial and final time periods examined.  Other 
oral cavity subsites remained relatively stable in incidence.   
  
  
Stage and Grade Trends of OCSCC 
OCSCC showed a steady trend toward earlier-staged disease (table 1), with an 
increase in AJCC stage 1 (+11%, p <.001) and a decrease in stages II-IV.   This was 
reflected in earlier T and N classifications.  There was a 14% increase in T1 disease, and 
corresponding decrease in T2 and T3.  Similarly, there was an increase in N0 and N1 
(+6% and +5.3%, respectively), with a concomitant decrease in N2 and N3.  M 
classification remained relatively stable over the study period at roughly 2% M1 disease.   
We further examined these staging trends for each individual subsite within the 
oral cavity.  We found that oral tongue tumors showed a dramatic trend towards earlier 
Figure 1 - OCC Subsite Incidence. Annual incidence rates for squamous cell 
carcinoma of each oral subsite averaged over five-year intervals.  The overall 
incidence of all subsites combined was decreased (not shown, p<.05). * indicates a 
significant change from first to last interval (p<.05).  FOM = floor of mouth, HP = 
hard palate, Retro = retromolar     
  
staging from the first to the final time periods, as the proportion diagnosed at stage 1 
disease increased from 27% to 44%, resulting in an absolute increase of 17% and a 
relative increase of 63%.  Other subsites showed mixed results with staging trends when 
observing absolute change in stage 1 disease (lip: -4%, gum: +10%, floor of mouth: +7%, 
hard palate: -9%, buccal: +6%, retromolar: +9%).  Overall, 62.9% of OT cancers were 
stage 1 or 2, compared to just 44.5% of other oral cavity cancers.  Other oral cavity 
cancers were also twice as likely as OT cancers to be stage 4 (40.4% vs. 19.7%). 
When examining T classification across individual subsites, there was a near 
unanimous increase in earlier staged disease, indicating that tumors throughout the oral 
cavity were routinely being detected at smaller sizes. In the first time period, 39% of oral 
tongue tumors were ‘T1’ disease (0-2 cm), compared with 55% in the final time period. 
Other subsites showed a similar increase in T1 disease from the first to the last periods 
(34% to 46%).  N classifications followed a similar trend, with nearly all oral cavity 
subsites showing an increase in stage N0 and N1 disease, and a concomitant decrease in 
N2 and N3 disease. M staging remained relatively stable for each subsite, changing less 
than 1% over time. 
Tumor grade remained fairly stable over time (table 1), though there was a 7% 
increase in Grade II (moderate differentiation), with a corresponding decrease in Grade I 
(well differentiated).  Notably, this increase in the ‘moderately differentiated’ group over 
time was consistently found in each subsite throughout the oral cavity. 
Treatment Trends in OCSCC 
  
In recent years, more patients with OCSCC received surgery, while fewer 
received only radiation (Table 1).  Since disease stage is one of the predominant 
determinants of treatment, we analyzed treatment trends within each stage (Table 3).  For 
stage 1 disease, there was an increase in ‘surgery only’ (79.5% to 85.1%, p<.01) and a 
decrease in the use of radiation in treatment (20.5% to 14.9%, p<.01).  This might 
represent an awareness of the morbidity associated with radiation therapy and a desire to 
spare the patient when a cure is achievable through surgical excision alone.  There was 
relatively little change in the management of stages 2 & 3, where both surgery and 
radiation are frequently used as standard of care.  Meanwhile, for stage 4 disease, there 
was an increase in radiation as the sole therapy (12.1% to 24.3%), with a concomitant 
decrease in surgical therapy (87.9% to 75.7%).  This could represent the decision by care 
providers not to perform surgery in a select group of late-disease stage patients in whom 
a cure is highly unlikely, who may not tolerate the procedure, and in whom quality of life 
is a priority.   
Over the past 20 years, there was also a gradual increase in the proportion of 
patients receiving neck dissections (+7.5%, p < .001) (Table 4).  This was especially 
pronounced for patients diagnosed with early staged disease (stages 1&2); this cohort was 
treated with a neck dissection only 19% of the time in 1988-92, and 26% in 2003-07, a 
relative increase of 36%.  There was no significant change in the percentage of late stage 
(stage 3&4) cases being treated with neck dissection, with roughly 50% of this cohort 
receiving neck dissections throughout the study periods. 
Distinct Demographic Affected by Oral Tongue (OT) Cancers 
  
Based on the paradoxical increase in OTSCC incidence, as well as previous 
reports of a shift in the epidemiology, we chose to further examine the characteristics of 
OTSCC.  Accordingly, oral tongue cancer was found to be quite different from other oral 
cavity subsites in its demographic characteristics.  First, it was seen to affect a younger 
population than other oral subsite cancers. The median age of OTSCC patients at 
diagnosis was 60 years, vs. 65 years for other oral subsites combined. There was also a 
trend toward a younger population over time for OTSCC, as the median patient age 
decreased from 63 years of age from 1988-92 to 59 years during the 2003-07 time period.  
A larger proportion of OTSCC affected females (43% of OT, 37.5% of other oral 
cancers), with a trend toward more females over the duration of the study period (+5%).  
With regard to race, the various subsites showed a similar breakdown of ‘White’, ‘Black, 
and ‘Other’ patients affected. The only salient difference between OT cancers and other 
subsites, was a greater proportion of ‘Other’ patients affected (in the final time period: 
10% for OT, 5.9% for all other subsites combined). Additionally, there was an increase in 
the number of ‘Other’ patients affected by OT cancers over time (7.7% to 10% from the 
first to the last time period).  As opposed to prior studies, we did not find an increase in 
the proportion of White individuals affected. 
Trends in Oral Cavity Cancer Survival 
Overall 5-year survival in OCSCC showed an absolute increase of 10.5% between 
1988-92 and 2003-07, from 39.9% to 50.4% (table 2) and cancer-specific 5-year survival 
increased 7.5% over the same period. Over the course of the four consecutive time 
periods examined, there is an incremental increase in overall survival (figure 2).  Though 
  
not included here, trends in relative survival calculated using the Ederer II method were 
very similar, showing a 10.6% increase in 5-year survival over the time periods.   
 
We next examined survival trends within subgroups of OCSCC.  The 5-year 
overall survival trend was examined across each clinical variable included in the study 
(table 2).  The youngest age groups (18-40, 41-55) experienced the greatest 
improvements in survival.  There was minimal change in the survival of the most 
advanced age group (85+).  Males appreciated a 13% increase in 5-year survival, 
compared to just 6% for women – leading to approximately equivalent survival rates in 
Figure 2 - OCC Survival By Period.  Kaplan Meier curves showing overall 
survival for OCSCC for each study time period.  Log rank comparing the 
first and last time periods was performed (p<.001). 
  
the most recent time period.  Whites had a higher 5-year survival than blacks in every 
time period.  However, black individuals experienced the highest increase in survival, 
with a near doubling of five year survival from the first to the last time periods in the 
study (from 19.4% to 35.3%).  Though the increase in survival of black individuals 
closed the historically large gap in survival of OCSCC between races, blacks still had the 
lowest five year survival of any racial group during the most recent time period (White: 
51.1%, Other: 55.2%, Black: 35.3%).  In order to further explore the historically lower 
survival rates in black individuals, we examined the clinical characteristics of this 
subgroup.  We found that, as compared to other racial groups, they were being diagnosed 
at later stages overall (>50% stage 4), and with more advanced T, N and M classifications 
on average.  
Survival Trends for Oral Tongue and other subsites 
From 1988 to 2007, survival improved for almost every oral subsite.  However, 
oral tongue demonstrated a particularly large increase in 5-year survival (+14.3% vs. 
+4% for all other subsites).  Our findings complicate the question of whether OT has a 
different prognosis from other oral subsites, as it appears that the answer has changed 
over time (figure 3).  In the first time period, OT cancers had a similar overall survival to 
other subsites, but by the final time period, it has a significantly higher five year overall 
survival.   
  
 
Treatment and Survival Trends 
While improved survival was found across all treatment categories, the increases 
were not uniform.  Patients who received surgery showed a greater improvement in 5-
year survival than those who received radiation only (+11.4% vs. +7.1%).  Additionally, 
patients who were treated with neck dissections experienced a larger increase in survival 
than those who did not (+15.9% vs. +8.1%).  It is not possible using the SEER database 
to determine whether this is due to improvement in therapy or simply changes in patient 
selection.  Although a randomized control trial would be a more appropriate way to 
answer such a question, it is unlikely that such a study could be performed. 
Figure 3 - Tongue vs. Non-Tongue Survival.  Kaplan Meier curves 
comparing overall survival for Tongue and Non-Tongue subsites.  ‘Non-
Tongue’ represents all other subsites in the oral cavity. 
  
Multivariate Analysis 
A univariate analysis using Cox proportional hazards regression was first used to 
determine which clinical variables correlated with survival.  Multivariate analysis was 
performed on the clinical variables which reached significance on univariate analysis 
(figure 4).  Even with all variables taken into account, there was a significant trend 
toward improved survival with subsequent time periods, as represented by decreasing 
Hazard Ratios (HR).  Meanwhile, age and stage classifications showed the largest, 
incremental effects on hazard ratios (HR).  Sex, race, and grade were also significant 
covariates.  Males had a higher HR than females, and blacks had the highest HR among 
races. 
Figure 4 - Multivariate Analysis.  Forest Plot demonstrating hazard ratios derived 
from multivariate Cox Proportional Hazards regression model.  All variables shown 
were included in the model.  M stage was not included in the model, as only M0 
patients 
  
 
The location of the primary within the oral cavity had very little effect on survival 
– visualized by the tight clustering of HR’s between different subsites (figure 4).  While 
OTSCC had a better survival than other subsites in the univariate analysis, this did not 
hold true in the multivariate model.  Interestingly, the OTSCC had a slightly higher HR 
than other oral cancers combined (figure 4).  Since we have already shown age and stage 
to exist in more favorable proportions in tongue cancers, we hypothesized that these 
variables were confounders for the subsite analysis.  To test this theory, when age and 
stage were subtracted from the model one at a time, the HR for OTSCC indeed fell below 
other that of sites. 
Genomic Analysis of Oral Tongue tumors 
Clinical Attributes of TCGA cohort 
We identified 511 HNSCCs available for analysis from the TCGA cohort. This was far 
more than the cohort of 279 tumors which was used in the recent HNSCC molecular 
characterization paper published by the TCGA [9].  There were 129 oral tongue tumors, 
and 178 other oral cavity tumors (‘oral cavity’ tumors herein include only oral subsites 
which are not the oral tongue).  The YNT (young, non-smoking, oral tongue) group 
accounted for 21 tumors, while the OST (old, smoking, oral tongue) group consisted of 
47 tumors.  Other subsite totals and characteristics can be found in Table 5. 
Similar to the SEER cohort, the TCGA OT cancers affected a younger population than 
other oral cavity subsites (mean age 58 vs 64).  Also corroborating SEER data, when 
compared with other anatomical sites, a larger proportion of the OT cancers affected 
  
females and non-smokers.  Notably, HPV testing was performed on 27 oral tongue, 28 
oral cavity, and 23 larynx/hypopharynx samples, and was reported positive by either p16 
or ISH testing in only 11%, 7%, and 17% of samples, respectively.  Conversely, 
oropharyngeal cancers were positive for HPV in 81% of samples tested.  This reaffirms 
the anatomical segregation of HPV involvement.  Since many other oropharyngeal 
tumors had not yet been tested at the time of this study, we group all OP tumors together, 
rather than only HPV+ tumors, assuming a high rate of HPV presence for the entire 
group. 
Somatic Mutations 
Of the 511 tumor cohort, 493 contained whole exome sequencing data.  Previous TCGA 
HNSCC studies used only 279 samples, so this represents the largest sample size to date 
for mutational analysis.  Because of the small sample size in the YNT cohort, we limited 
our initial search to genes reported by the TCGA as being most commonly mutated in 
HNSCC.  Table 6 shows the frequency of non-silent mutations in these genes.  The 
average mutation rate in the YNT cohort was 65, compared to 120 mutations for the OST 
group.  This is not necessarily surprising given that mutation rates have been shown to 
increase with age and tobacco exposure.  Meanwhile, the overall oral tongue group (OT) 
had far fewer mutations than the rest of the oral cavity (94 vs. 175, p < .01), even when 
accounting for smoking status/age differences.  This finding has not been previously 
established. 
The YNT group actually displayed a significant increase in the rate of mutations to cell 
cycle regulators p53 and CDKN2A (91% and 43%, respectively; p < .05 for each), when 
  
compared to all other tumors.  This is in stark contrast to HPV-related oropharyngeal 
(OP) cancers, which showed dramatically decreased rates of 29% and 7% for p53 and 
CDKN2A, respectively. The YNT group thus lacks important, classic signatures of 
HPV+ tumors (absence of CDKN2A and p53 mutations), which results from expression 
of the HPV oncoproteins E6 and E7.  With the exception of p53 and CDKN2A, almost 
every other gene examined here showed a decreased mutation rate in the YNT group, 
although none reached significance, possibly due to the small cohort size of YNT.  
Several genes showed a trend toward decreased mutation rate (FAT1, CASP8, PIK3CA, 
NSD1) which could be better evaluated with a larger sample size.   
When comparing OT to 
other OC subsites, there 
was a significantly 
decreased mutation rate 
in FAT1 and CASP8.  
This is an interesting 
finding in the context of 
the recent TCGA 
publication which 
showed a unique sub-
population of tumors 
with mutated CASP8 and 
HRAS mutations and 
possessing a superior 
Figure 5 - Mutation heat map illustrating non-silent mutations (Blue stripes) in 
the most commonly mutated genes of the TCGA published cohort.  Samples 
are aligned horizontally.  OT = Oral Tongue, OC = Oral Cavity (not including oral 
tongue), OP = Oropharynx, L/H = Larynx/Hypopharynx.  The dotted line at the 
top left borders the left-most, YNT group. 
  
prognosis [9].  Based on our results, this subtype may be segregated to another oral cavity 
subsite, possibly the buccal mucosa (8/15 with CASP8 mutation) and hard palate (2/4 
with CASP8 mutation).  These rates are extremely high, and reach significance when 
compared to the rest of the head and neck (14/318 = 4%).  Figure 5 illustrates the 
commonly mutated genes across the samples included in each cohort. 
To conclude our mutational analysis, we searched for mutations enriched in our cohorts 
which have not been previously well described.  To do so, we examined the whole exome 
sequences of each cohort to find the most highly mutated genes in each anatomical 
subgroup. The results can be found in table 7.  Briefly, this simply shows that very few 
genes are recurrently mutated in the YNT group.  Only a few genes were mutated in 
>20% of cases, and none of these were unique to the YNT cohort and/or more commonly 
mutated than in other cohorts. 
 
Copy Number Analysis 
Copy number data were available in all 511 tumors in our cohort.  Previous analysis by 
the TCGA group and others had shown recurring copy number alterations (CNAs), 
consisting of losses of 3p and 8p, and gains of 3q, 5p and 8q chromosomal regions.  
These CNAs are driven by loss of tumor suppressors or gains in oncogenes, resulting in a 
competitive advantage to cells containing these defects.  With a mean of 141 CNAs per 
tumor, HNSCC shows a high degree of instability relative to most types of cancers.  
Figure 6 displays the copy number profile of the YNT and OST cohorts, as well as the 
parent OT cohort and OC cohort.  Across the head and neck subsites, the copy number 
  
profiles (proportion of each locus which is amplified, deleted, or normal) are very similar 
to one another.  The profile of the oropharyngeal subset is noticeably different – likely 
due to its unique pathogenesis and selective pressures. The copy number profile of the 
YNT cohort resembles that of the traditional head and neck cohorts more closely than it 
resembles oropharyngeal cancers, indicating that its causative mechanism may be 
dissimilar from HPV-related tumors.  There was an increased incidence of 11p13 
amplification in YNT compared to all other cohorts.  Meanwhile, OT tumors overall 
showed an increased loss of 4q and 5q compared to other oral cavity tumors (p < .05, 
using fisher’s exact test at each chromosomal locus). 
Figure 6 – Copy number changes (Gistic 2.0, thresholded), viewed grossly across all 
chromosomes to highlight commonly recurring amplification (red) and deletions (blue).  
Colors illustrate the proportion of samples which are amplified (red), deleted (blue), or 
normal (white) at each locus.  Darker blue indicates homozygous deletion, lighter blue 
heterozygous.  Darker red indicates exceedingly high copy number.  CNAs are shown for 
each anatomical group 
  
 
Mutation+CNA Analysis 
Several different types of genetic alterations can lead to a similar outcome (loss of a 
tumor suppressor or activation of an oncogene).  We integrated mutational and CNA data 
in order to identify genes most commonly affected in HNSCC irrespective of the type of 
defect.  We segregated samples as in the previous analyses, and focused on genes 
previously implicated in HNSCC[9].  Figure 7 shows the frequency and type of alteration 
in each gene/pathway.  The YNT cohort can be found at the very left of the figure, and 
shows an overall decreased frequency of alterations.  Specifically, the PIK3CA pathway, 
cell death pathway, and oxidative stress pathway show almost no defects for this cohort.   
 
  
Expression Analysis 
We sought to explore differences in gene expression among our clinical cohorts, focusing 
on the differences between oral tongue and other oral cavity subsites (OT v OC) as well 
as distinct expression signatures within the oral tongue subgroups (YNT v OST). With 
expression data available for 20530 genes across 511 samples, we first found the most 
Figure 7 – Mutation+CNA data for each sample.  This oncoprint show samples horizontally, 
divided by anatomic origin (same as figures 5/6).  The gene listing is vertically divided 
according to common biological pathways involved in cancer. 
  
differentially expressed genes (DEGs) between YNT and OST.  165 genes were 
significantly more highly expressed in YNT and 116 genes in the OST group (FDR < .05, 
p < .001).  We examined these genes for over-representation of biological pathways using 
the Gene Ontology (GO) enrichment tool.  Ion binding was the only enriched function in 
YNT tumors, and no functions or pathway were enriched in OST. 
Since there was the gene expression among the oral tongue subgroups was fairly 
homogenous based on pathway analysis, we then found the DEGs between OT and OC.  
1500 genes were significantly more highly expressed in OT and 673 genes in the OC 
group (FDR < .05, p < .001).  We again examined these genes for over-representation of 
biological pathways using the Gene Ontology (GO) enrichment tool.   The most 
upregulated genes in the OT group were almost exclusively muscle-related genes (p < 
.00001, GO Enrichment), likely due to the presence of muscle cells in the oral tongue 
cancer specimen.  To screen for relevant genes, we performed the same analysis without 
muscle-related genes – and found that cell differentiation, nervous system development, 
cellular response to DNA damage, DNA repair, DNA metabolic process, and mitotic 
functions were each enriched.  Those genes which were upregulated in OC cancers 
compared to OT cancers were enriched for: cell cycle processes, G2/M phase transition, 
mitosis, DNA replication, DNA repair, assembly of cellular components. Olfactory 
response and response to bacterium were also upregulated, likely as a by-product of the 
normal functions of oral cavity tissue (i.e. contamination). 
We next performed an unsupervised hierarchical clustering of all 511 samples using the 
3600 genes which were most variably expressed in the samples, as described previously 
[47, 48].  Figure 8 shows the resulting dendrogram.  Roughly four distinct expression 
  
subtypes were found, and anatomical sites segregate highly into each of these.  
Oropharynx, Larynx, Oral Tongue and Oral Cavity tumors (from left to right) comprised 
the bulk of each subtype.  The fact that OT tumors clustered separately from most other 
oral cavity tumors suggest they possess a distinct expression profile.  The YNT did not 
cluster tightly within the OT tumors, indicating that they do not have a unique or distinct 
profile from other OT tumors. 
To examine whether OT was comprised of multiple sub-types, and determine whether the 
YNT group possessed a unique expression signature, we performed an unsupervised 
clustering of only OT tumors.  Figure 9 shows that while multiple subgroups were found, 
they were much more closely related than the subgroups of figure 8.  YNT did not cluster 
with one another, and in fact no clinical markers examined (tobacco use, gender, race, 
age) were significantly associated with a single expression profile.  OT cancers appear to 
consist of a fairly homogenous expression profile. 
 
 
 
 
  
 
Figure 8 – Unsupervised mRNA expression analysis of HNSCC 
1. Clinical T: Darker blue = higher stage (T1-T4) 
2. Clinical N: Darker Red  = positive nodes 
3. PN Inv  = Perineural Invasion: Black = Yes 
4. LV Inv = Lympho-Vascular Invasion: Black = Yes 
5. Vital Status: Black = Dead 
6. Female: Blue = yes 
7. HPV+: Blue = positive p16 or ISH 
8. Tobacco Use: Black = smoker, gray = unknown 
9. Age: Light Red = < 55, Dark red =  55+ 
10. Subgroup Category: Light Yellow = YNT, Dark Yellow = OT, Light blue = OC, Light Green = HPV+, Dark Green = 
OP, Red = LH 
Following unsupervised clustering using 3600 genes, it can be observed that anatomical sited, cluster 
quite closely to one another, including OT vs OC. 
  
Discussion 
Changing Characteristics of OCSCC 
Using the SEER database, we found that the OCSCC characteristics and survival 
changed over the past 20 years.  The affected patient population became younger and  
Figure 9 – Unsupervised mRNA expression analysis of OTSCC 
 OT Category: Yellow – YNT, Red = OST,  Blue = Remaining OT 
Following unsupervised clustering using 3600 genes, it can be observed that OTSCC does 
not cluster into well defined clinical groups, as visualized by the scatter of blue, red and 
yellow at the bottom of the figure.  Overall, OTSCC appears to represent a fairly 
homogenous expression group. 
  
more female, while tumors were diagnosed at earlier stages.  Specifically, oral tongue 
cancers were largely responsible for the observed changes.  Additionally, while the 
incidence of SCC within most oral subsites declined, OTSCC incidence increased over 
the study period  and this finding is supported by previous reports of a change in the 
epidemiology of OTSCC [22].  However, despite implications that this epidemiological 
shift may entail a new causative mechanism, tumors from the oral tongue subsite could 
not be distinguished from other tumors of the oral cavity based on current molecular data.  
The decrease in incidence of floor of mouth cancers has not been previously described, 
but interestingly the decrease in floor of mouth cancer closely mirrors the rise in oral 
tongue cancers. It is possible that a change in environmental risk factors, such as a 
decline in the usage of chewing tobacco, has led to this decline in incidence of floor of 
mouth cancers.  Alternatively, it is possible that changes in coding patterns of the primary 
tumor location has led to fewer cancers being labeled as ‘floor of mouth’ and instead 
being attributed to adjacent subsites. In addition, with OTSCC being diagnosed at smaller 
sizes, it is possible that ventral tongue cancers are less frequently being labeled as floor of 
mouth cancers. More study is required to further detail this trend and explore these 
possibilities. 
Improving OCSCC Survival  
While traditional thought has been that survival in oral cavity cancers has not 
improved during the last several decades, data reported here show that survival for 
OCSCC has gradually improved over the past 20 years (HR = 0.81). In opposition, 
Carvahlo et al used the SEER database to show that while many types of head and neck 
cancers showed improved prognosis from 1973-1999, oral cavity cancer survival did not 
  
[28].  However, several more recent studies support our analyses [23, 26, 27].  Pulte et al 
performed a period analysis of the SEER database (1982-2006) revealing a significant 
increase in survival of oral cavity and oral tongue cancers[26].  Mehta et al used the 
SEER database (1975-2006) to stratify tumors by histologic grade and came to similar 
findings[27]. Importantly, both of these studies used the ‘Tongue’ category site code, 
which includes tumors of the base of tongue and other lesions as possible confounders. 
To understand the significance of this inclusion, we analyzed the ICD codes of cases 
within the ‘Tongue’ category.  We found that over half (66%) of these cancers consisted 
of likely oropharyngeal subsites including: ‘base of tongue’ (47%), ‘lingual tonsil’ (1%), 
‘overlapping lesions’ (3%), or ‘tongue, NOS’ (15%).  Exclusion of non-oral cavity 
carries particular significance considering the distinct epidemiology, molecular 
characteristics, clinical characteristics, and prognosis of oropharyngeal cancers, which are 
mostly HPV-related.  More recently, Saba et al performed an analysis of survival using 
ICD codes more precisely distinguishing between oral cavity and oropharynx [23], and 
found improved survival for both oral tongue and base of tongue lesions. In a 
retrospective, international study of 2,738 patients who underwent resection for OCSCC, 
Amit et al found a significant improvement in survival from the 1990’s – 2000’s[30].  
Our findings build on these recent reports using a larger and more recent cohort from 
SEER data, and with a detailed trend analysis of patient, clinical, and treatment 
characteristics.  
Prognosis of Oral Tongue vs. Other Subsites 
Though nearly all subsites experienced an improvement in five year survival, oral 
tongue cancers experienced the greatest jump.  In the final time period, oral tongue 
  
cancers had a five year survival of 58.6%, versus just 42.8% for all other oral cavity 
subsites.  However, the apparent superior prognosis of OTSCC was found to be 
attributable to a favorable stage and age profile, but not specifically to the oral tongue 
subsite based on multivariate analysis. The most important covariates correlating with 
improved survival of OTSCC were stage, age, and grade (figure 4).  Also using 
multivariate analysis, we show that the prognosis of oral tongue cancers compared to 
other oral subsites has not significantly changed over time.  We are the first to examine 
subsite survival trends to show this, using rigorous criteria which exclude oropharyngeal 
subsites in the SEER database.  The analyses here help clarify a widely debated topic in 
the literature, as to whether prognosis for oral cavity cancers vary based on subsite.  
Single institutional studies relying on smaller cohorts have reported mixed results with 
regard to differences in prognosis based on subsite within the oral cavity [13, 16-18].  
Using the SEER database, Rusthoven et al  [15] concluded that earlier stage tongue 
cancers had a poorer 5-year overall and disease-specific survival compared to other early 
stage oral cavity cancers.  Our univariate analysis, by examining this relationship over 
time, found that survival patterns have been changing over the past twenty years.  Twenty 
years ago, OT had an overall worse prognosis than many other oral cavity subsites, and 
this may be contributing to the conflicting reports.  This trend also coincides in time with 
rising incidence of OTSCC and its association with a younger cohort being diagnosed at 
earlier stages.  While our analyses and results confirm previous studies identifying a shift 
in the epidemiology of oral tongue cancers [1, 22, 49, 50], the correlations identified are 
unable to explain why oral tongue cancers are being diagnosed at earlier stages and in a 
younger population.   
  
Clinical Relevance of the Epidemiological Shift 
As the characteristics and patient population of OCSCC evolves over time, it is 
important for care providers to stay up to date regarding these changes.  For example, 
OCSCC should no longer be considered a disease restricted to an older population or 
males. When a suspicion of malignancy arises, the same care and precaution should be 
taken regardless of age or gender.  Care providers should also understand the prognosis 
and natural course of the disease, which includes understanding the clinical factors which 
affect survival.  This would allow them to adjust their treatment strategies, and keep their 
patients up to date and informed.  Additionally, with the various changes to treatment 
protocols over the past twenty years, it remains important to determine the effect of these 
changes on the survival of patients, and measure our progress in combatting OCSCC.  In 
the same vein, by capturing incidence and staging trends over time, we can also measure 
the effectiveness of primary cancer prevention and early detection methods. 
If the epidemiological shift of OCSCC or OTSCC is due to a new causative agent, 
identification of this agent through follow-up study may allow the development of novel 
strategies for primary prevention, as well as diagnostic or treatment methods specific to 
the etiology.  The identification of HPV as a causative agent of oropharyngeal cancer 
spurred the development of diagnostic tests such as p16 expression assays and PCR based 
viral detection methods.  It also has driven intense research into novel targeted drugs and 
alternative/de-escalated treatment protocols.  Studying the genetic and molecular 
characteristics can help identify new attributes in this subset of tumors, but further study 
of these individual tumors, the oral microbiome, and other potential exogenous 
carcinogens would be necessary to identify any new causative agents.  An appropriate 
  
first step might be testing these samples for the presence of known oncogenic viruses or 
other strains of HPV. 
Genomic Analysis of OTSCC 
Previous genomic analyses of HNSCC have examined characteristics of the oral cavity as 
a whole, but very few have focused efforts on the oral tongue or individual oral subsites.  
The recently published TCGA paper [9] performs similar analyses for HNSCC as a 
whole, but without focusing on OT or YNT cohorts, as we have.  One analysis, published 
very recently, examines a similar OT and YNT cohort, but focuses more on the types of 
mutations (e.g. C->A vs C->T), concluding that the OT group mutation profile resembles 
a ‘smoking’ signature, despite being mostly non-smokers[34]. They also utilize a smaller 
sample size (n = 323), which did not allow statistical power to find uniquely affected 
genes.  Having access to the largest cohort of samples yet reported (n = 511), here we 
show that oral tongue tumors in the TCGA cohort carried similar clinical characteristics 
to OT patients in the SEER population (e.g. younger, more female, more non-smokers).  
We demonstrate that the overall mutation rate is significantly lower in OT cancers 
compared to other cancers of the OC and head and neck.  The YNT cohort has the lowest 
mutation rate of all, and carries fewer mutations in most cancer-related genes – with the 
fascinating exception of increased mutation rates in p53 and CDKN2A, both of which 
play critical roles in cell cycle regulation. 
There was a similar copy number profile amongst OT tumors regardless of age and 
smoking status, and this profile resembled that of other ‘traditional’ head and neck 
cancers at almost every locus, with an additional amplification at 11p.  This profile is 
  
very different from HPV-related tumors of the oropharynx, and could indicate that the 
selection pressures for CNAs in OT cancers is similar to that of traditional HNSCC 
related to smoking and environmental exposures.  Lastly, the expression profile of OT 
tumors was distinct from that of other sites in the oral cavity.  This is a previously 
unrecognized phenomenon, though the significance of this finding is unclear, and it is 
difficult to determine how much of this effect is due to contamination by native tissue 
(e.g.. muscle in the tongue).  A search for a unique molecular trademarks (e.g. enriched 
mutations or CNAs) in this expression subgroup, as well as characterization of the gene 
ontology of the DEGs would be prudent. 
While the genomic analyses do not have the ability to directly identify an etiological 
agent, they do show that OT cancers are a fairly homogenous group (even YNT closely 
resembled OST), and do resemble traditional, smoking-related oral cavity cancers.  Given 
the molecular profile similarities amongst OT cancers and between older smokers and 
younger non-smokers, and their difference from the molecular profile of HPV-associated 
HNSCC, it is unlikely that HPV or a similar-acting oncogenic virus is involved in the 
etiology. It is more likely that secondhand smoke or another environmental exposure is 
involved in the etiology of OT cancers in non-smokers. 
Changes in Five Year Survival 
There are many possible causes of a change in 5-year survival, though many are 
beyond the scope of analysis using the SEER database.  Conceptually, an improvement in 
5-year disease survival can be due to changes in 1) the underlying disease (etiology), 2) 
changes in diagnosis/early detection (lead time),  3) more effective treatment of the 
  
disease (management), 4) or changes in the affected population (age or comorbidities).  
Though the majority of these possibilities cannot be fully explored through the SEER 
database, we discuss them here for the possibility of future investigation into these trends  
Regarding etiology and the affected population, the primary causes of head and 
neck SCC have long been considered environmental carcinogens such as tobacco and 
alcohol.   However, an increasing number of non-smoking, non-drinking patients are 
being affected.  The finding that OTSCC affects a different demographic [50] could be an 
indication that the etiologic landscape of OCSCC (especially oral tongue cancer) is 
changing.  Rates of HPV related cancers are clearly on the rise [19, 51], and have an 
improved prognosis compared to HPV-negative HNSCC [52, 53], but HPV is rarely 
found in oral cavity cancers.  As speculated above, other HPV strains, tumorigenic 
viruses, or even other environmental causes could all be possible drivers of this change.  
Myers et al ([34]) recently analyzed the molecular characteristics of OTSCC in young, 
non-smoking patients and found that cancers from this younger, non-smoking cohort 
were very similar to OTSCC in older, smoking patients, and very different from HPV-
related cancers of the head and neck.  This makes it unlikely that HPV is causing these 
tumors. Regardless, it may be that diagnosis of OCSCC in a younger non-smoking cohort 
will improve overall survival based on natural lifespan and fewer recognized or 
unrecognized comorbid conditions in the non-smokers.  
Regarding early detection, we observed improvements in survival for every stage, 
so it is unlikely that earlier detection or stage migration alone accounts for all of the 
effect seen.  However, we did find a trend towards lower stages at diagnosis over time, 
driven by lower T and N classification upon diagnosis. Diagnosis at lower stage was 
  
found despite rigorous guidelines and newer technologies that would tend to lead to 
higher staging of patients.   No population-based screening programs have been 
implemented in the US, and existing smaller screening programs (such as OHANCAW 
[54]) have not been studied to determine their effectiveness on a population scale. 
With respect to management, the treatment of OCSCC has evolved as well. We 
found that more surgery and neck dissections were being performed, especially for early 
stage disease.  Later stages and older age groups were being treated with less surgery and 
more radiation, possibly indicating recognition of when palliation is the best approach.  
Treatment has also evolved in many ways which we could not evaluate.  Some of these 
include: emphasis on negative margin surgical resection, improvements in reconstructive 
surgical techniques, better chemo-radiotherapy regimens, a defined role for selective and 
elective neck dissections [55], new targeted drugs [56, 57], and advances in radiotherapy 
such as intensity modulated radiotherapy and hyperfractionation [58, 59].  Though 
speculative, it also is possible that greater access to these standards, or a transition to care 
at higher-volume academic centers has resulted in better outcomes overall. 
Limitations 
While SEER provides a large sample size from which to calculate incidence and 
survival, it has limitations as well [60].  Though SEER records data from roughly 26% of 
the US population, it does not necessarily represent the entire United States.  Use of a 
national database is also limited by variations in data reporting among sites, incomplete 
data entry, and migration of patient populations, though SEER is audited to limit such 
errors [60].  For our purposes, there was no information on tobacco/alcohol use, 
  
chemotherapy, HPV status, and many other clinical/treatment variables which might 
influence incidence and survival.  Single or multi-institutional studies would be better 
suited for examining trends in these variables with respect to survival.  It should also be 
noted that trends in 5-year survival do not directly equate to trends mortality or 
prognosis, due to confounding factors such as changing diagnostic habits [61] and 
changes in incidence.  Lastly, because of a shorter follow up time, the number of 
censored patients increases with more recent time periods, which may increase the 
likelihood of bias.   
Conclusion 
In conclusion, survival has improved in OCSCC.  Our analysis suggests that this 
may be partially related to detection at earlier stages and a younger/healthier population 
affected.  It is possible that improvements in diagnostics and treatment, or even a change 
in the disease etiology are also playing a role. Further study of each of these individual 
elements, such as a retrospective analysis of the treatment modalities used at a single 
institution over the years, may help delineate the specific causes for the increase in 
survival.  
Oral tongue SCC survival has improved even more dramatically than OCSCC 
over the past 20 years, and now carries a significantly better prognosis compared to other 
subsites.  This improvement correlated to diagnosis at earlier stages and in a younger 
population. Analysis of genomic data revealed that OT cancers form a distinct molecular 
subtype.  Further study of this subset of tumors, the oral microbiome, and other potential 
exogenous carcinogens would be necessary to identify any new causative agents. 
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Tables 
Table 1 – Patient, Tumor, and Treatment Characteristics By Period 
 
1988-92 1993-97 1998-02 2003-07 change p value 
% n % n % n % n 
 
Age 
         
p < 0.001 
18-40 5.2% (114) 5.9% (169) 6.3% (306) 4.9% (313) -0.3% 
41-55 20.7% (455) 23.1% (661) 26.6% (1,299) 26.5% (1,688) +5.8% 
56-70 39.2% (861) 34.4% (983) 32.1% (1,570) 35.4% (2,254) -3.8% 
71-85 29.1% (639) 30.9% (885) 28.6% (1,397) 26.5% (1,683) -2.7% 
85+ 5.7% (125) 5.7% (162) 6.4% (312) 6.6% (422) +0.9% 
Total 
 
(2,194) 
 
(2,860) 
 
(4,884) 
 
(6360) 
 
         Sex 
         
p < 0.001 
Female 35.6% (782) 41.6% (1,189) 40.3% (1,968) 39.3% (2,499) +3.6% 
Male 64.4% (1,412) 58.4% (1,671) 59.7% (2,916) 60.7% (3,861) -3.6% 
Total 
 
(2,194) 
 
(2,860) 
 
(4,884) 
 
(6,360) 
 
         Race 
         
p = 0.001 
Black 9.5% (207) 9.6% (273) 8.9% (432) 8.1% (508) -1.4% 
Other 5.0% (110) 7.1% (203) 6.4% (307) 7.5% (469) +2.5% 
White 85.5% (1,872) 83.3% (2,366) 84.7% (4,094) 84.4% (5,297) -1.1% 
Total 
 
(2,189) 
 
(2,842) 
 
(4,833) 
 
(6,274) 
 
         Primary site 
         
p < 0.001 
lip 4.2% (93) 4.0% (113) 5.4% (266) 4.8% (306) +0.6% 
tongue 30.1% (660) 32.5% (929) 35.7% (1,744) 37.8% (2,405) +7.7% 
gum 12.3% (269) 13.3% (381) 12.5% (611) 13.1% (830) +0.8% 
floor of mouth 34.2% (751) 30.3% (867) 26.5% (1,296) 23.7% (1,508) -10.5% 
hard palate 2.1% (46) 3.3% (94) 3.3% (160) 3.2% (202) +1.1% 
buccal 7.6% (167) 7.6% (218) 8.8% (428) 9.5% (605) +1.9% 
retromolar 9.5% (208) 9.0% (258) 7.8% (379) 7.9% (504) -1.6% 
Total 
 
(2,194) 
 
(2,860) 
 
(4,884) 
 
(6,360) 
 
         Grade 
        
p < 0.001 
Well diff. 32.6% (588) 26.7% (659) 25.7% (1,077) 26.0% (1,416) -6.6% 
Mod. diff. 49.2% (887) 52.9% (1,306) 56.1% (2,353) 56.2% (3,062) +7.0% 
Poorly  diff. 17.7% (328) 19.9% (502) 17.7% (768) 17.5% (971) -0.3% 
Total 
 
(1,803) 
 
(2,467) 
 
(4,198) 
 
(5,449) 
 
         Stage 
         
p < 0.001 
1 22.5% (269) 24.7% (419) 28.5% (906) 34.0% (1,685) +11.4% 
2 24.4% (291) 24.2% (409) 21.1% (671) 19.3% (959) -5.0% 
3 19.5% (233) 14.8% (251) 14.9% (474) 15.6% (776) -3.9% 
4 33.6% (401) 36.3% (614) 35.4% (1,126) 31.0% (1,539) -2.6% 
Total 
 
(1,194) 
 
(1,693) 
 
(3,177) 
 
(4,959) 
 
         T stage 
         
p < 0.001 
T1 27.3% (398) 30.7% (613) 34.2% (1,198) 40.7% (2,045) +13.4% 
T2 35.4% (516) 33.5% (669) 30.4% (1,065) 30.2% (1,516) -5.2% 
T3 14.2% (207) 12.1% (242) 11.7% (408) 11.6% (581) -2.6% 
T4 23.1% (337) 23.8% (476) 23.7% (831) 17.6% (882) -5.6% 
Total 
 
(1,458) 
 
(2,000) 
 
(3,502) 
 
(5,024) 
 
         N stage 
         
p < 0.001 
N0 62.6% (1,015) 66.4% (1,477) 67.7% (2,833) 68.4% (3,989) +5.8% 
N1 7.5% (122) 7.4% (164) 7.7% (324) 12.9% (751) +5.4% 
N2 28.6% (464) 25.1% (559) 23.7% (990) 17.6% (1,027) -11.0% 
N3 1.3% (21) 1.2% (26) 0.9% (38) 1.1% (67) 
 
Total 
 
(1,622) 
 
(2,226) 
 
(4,185) 
 
(5,834) 
 
         M stage 
         
p = 0.739 
M0 98.1% (1,999) 97.8% (2,618) 97.7% (4,542) 97.9% (5,794) -0.1% 
M1 1.9% (39) 2.2% (58) 2.3% (107) 2.1% (122) +0.1% 
Total 
 
(2,038) 
 
(2,676) 
 
(4,649) 
 
(5,916) 
 
         Treatment 
         
p < 0.001 
surgery 49.1% (981) 47.2% (1,219) 49.9% (2,160) 52.7% (2,972) +3.5% 
surgery+rad 34.0% (678) 36.5% (944) 34.5% (1,493) 32.5% (1,837) -1.4% 
rad only 16.9% (338) 16.3% (420) 15.6% (676) 14.8% (835) -2.1% 
Total 
 
(1,997) 
 
(2,583) 
 
(4,329) 
 
(5,644) 
 
         Neck dissection 
         
p < 0.001 
no 75.4% (1,624) 73.9% (2,095) 69.2% (3,330) 67.9% (4,187) -7.5% 
yes 24.6% (530) 26.1% (740) 30.8% (1,480) 32.1% (1,981) +7.5% 
Total 
 
(2,154) 
 
(2,835) 
 
(4,810) 
 
(6,168) 
 
  
 
Table 1. Temporal trends of patient, tumor, and treatment characteristics, shown as proportions of the total case-
load.  The number of cases (n) are shown in parenthesis, and the absolute change in proportion from the first to last 
time period is found in the right-most column.  Gender, Other = American Indian/AK Native, Asian/Pacific Islander. 
 
 
Table 2 – Five Year Overall Survival By Period 
1988-92 1993-97 1998-02 2003-05 change p value 
Overall 39.9% 41.3% 45.2% 50.4% +10.6% <0.001 
Age 
      
18-40 64.0% 63.3% 64.9% 74.4% +10.4% 0.030 
41-55 46.1% 52.3% 55.5% 58.6% +12.5% <0.001 
56-70 42.6% 43.2% 49.0% 50.4% +7.7% <0.001 
71-85 31.8% 31.0% 33.0% 38.0% +6.2% 0.005 
85+ 16.0% 17.3% 14.5% 16.5% +0.5% 0.448 
Sex 
      
Female 43.9% 44.1% 44.4% 50.1% +6.3% 0.002 
Male 37.8% 40.1% 46.0% 50.6% +12.7% <0.001 
Race 
      
Black 19.4% 25.4% 30.9% 35.3% +15.9% <0.001 
Other 42.1% 50.3% 41.7% 55.2% +13.1% 0.030 
White 41.9% 42.6% 46.9% 51.1% +9.1% <0.001 
Primary site 
     
lip 65.4% 74.9% 74.5% 70.1% +4.7% 0.222 
tongue 44.3% 48.5% 52.9% 58.6% +14.3% <0.001 
gum 40.6% 40.7% 44.2% 47.7% +7.1% 0.031 
floor of mouth 36.2% 36.4% 39.2% 41.6% +5.5% 0.011 
hard palate 45.5% 28.9% 30.4% 43.0% -2.4% 0.610 
buccal 36.8% 34.6% 32.0% 43.5% +6.7% 0.075 
retromolar 28.2% 30.5% 34.3% 39.6% +11.4% 0.004 
Grade 
    
Well diff. 50.0% 53.2% 57.0% 59.4% +9.4% <0.001 
Moderately diff. 35.9% 39.2% 43.4% 49.3% +13.4% <0.001 
Poorly  diff. 26.9% 27.9% 29.2% 37.3% +10.4% 0.005 
Stage 
      
1 66.8% 68.5% 72.7% 73.4% +6.6% 0.045 
2 41.4% 47.9% 54.5% 52.8% +11.4% 0.009 
3 28.8% 27.3% 33.2% 41.0% +12.2% 0.005 
4 20.3% 22.9% 27.0% 24.9% +4.6% 0.256 
T stage 
      
T1 41.9% 42.6% 46.9% 51.1% +9.1% 0.042 
T2 38.3% 38.5% 45.2% 46.7% +8.3% 0.020 
T3 24.5% 29.0% 29.2% 29.7% +5.2% 0.466 
T4 24.2% 26.1% 27.6% 25.4% +1.2% 0.709 
N stage 
      
N0 50.8% 53.8% 57.2% 61.1% +10.3% <0.001 
N1 20.7% 20.5% 27.7% 36.5% +15.8% <0.001 
N2 17.5% 16.6% 20.3% 22.9% +5.4% 0.057 
N3 0.0% 4.0% 13.6% 12.6% +12.6% 0.648 
M stage 
      
M0 41.2% 43.0% 46.4% 51.5% +10.2% <0.001 
M1 5.4% 10.3% 11.0% 3.8% -1.6% 0.699 
Treatment 
     
surgery 57.9% 60.6% 64.9% 69.3% +11.4% <0.001 
surgery+rad 32.8% 32.1% 36.9% 44.2% +11.4% <0.001 
rad only 11.3% 15.8% 15.6% 18.4% +7.1% 0.048 
Neck dissection 
     
no 41.8% 43.5% 46.1% 49.9% +8.1% <0.001 
yes 34.8% 37.3% 43.7% 50.7% +15.9% <0.001 
  
Table 2.  Overall 5-year survival stratified by all patient, tumor, and treatment characteristics.  In the right-most 
column is the change in survival rate from the first to last time period.  Gender: Other = American Indian/AK Native, 
Asian/Pacific Islander.  Note that survival only includes the years 2003-05 for the final time  period. 
 
Table 3 - Treatment by stage over time 
Stage 1 
 
1988-92 1993-97 1998-02 2003-07 Change 
 
Surgery 79.5% 80.2% 82.7% 85.1% 5.7% 
 
Surgery+Rad 16.8% 17.3% 14.7% 11.9% -4.9% 
 
Radiation Only 3.7% 2.4% 2.6% 2.9% -0.8% 
Stage 2 
 
1988-92 1993-97 1998-02 2003-07 
 
 
Surgery 55.2% 59.3% 57.5% 51.3% -3.9% 
 
Surgery+Rad 31.3% 27.5% 31.5% 34.7% 3.5% 
 
Radiation Only 13.5% 13.1% 11.0% 14.0% 0.4% 
Stage 3 
 
1988-92 1993-97 1998-02 2003-07 
 
 
Surgery 27.2% 18.9% 27.0% 28.3% 1.1% 
 
Surgery+Rad 54.8% 60.1% 55.0% 55.1% 0.2% 
 
Radiation Only 18.0% 21.0% 18.0% 16.6% -1.4% 
Stage 4 
 
1988-92 1993-97 1998-02 2003-07 
 
 
Surgery 27.5% 20.4% 20.9% 18.1% -9.3% 
 
Surgery+Rad 60.4% 63.4% 63.8% 57.6% -2.8% 
 
Radiation Only 12.1% 16.2% 15.3% 24.3% 12.1% 
 
Table 4 - Neck Dissection by stage over time 
Stage 1 
 
1988-92 1993-97 1998-02 2003-07 Change 
 
no 89.0% 84.0% 81.1% 78.5% -10.4% 
 
yes 11.0% 16.0% 18.9% 21.3% 10.3% 
Stage 2 
 
1988-92 1993-97 1998-02 2003-07 
 
 
no 73.6% 72.6% 70.5% 66.5% -7.1% 
 
yes 26.1% 27.4% 29.5% 33.5% 7.4% 
Stage 3 
 
1988-92 1993-97 1998-02 2003-07 
 
 
no 48.4% 51.9% 46.8% 47.0% -1.3% 
 
yes 51.6% 48.1% 53.2% 52.6% 1.0% 
Stage 4 
 
1988-92 1993-97 1998-02 2003-07 
 
 
no 47.3% 42.7% 41.9% 49.5% 2.3% 
 
yes 52.2% 57.1% 58.0% 50.1% -2.2% 
 
 
 
  
Table 5 – Clinical Attributes of TCGA Cohort 
 
 Oral Tongue Other Oral Cavity Oropharynx Larynx/Hypopharynx Total 
N 129 178 81 123 511 
Age < 55 49 47 38 28 162 
Age > 55 78 133 43 95 349 
Mean Age 58.0 64.2 55.9 62.1 60.8 
Female % 36.4% 31.5% 14.8% 17.9% 26.8% 
White % 85.3% 85.4% 92.6% 80.5% 85.3% 
Smoker 74 130 51 111 366 
Non-Smoker 52 41 29 9 131 
Unknown 3 7 1 3 14 
% Smokers 58.7% 76.0% 63.8% 92.5% 73.6% 
HPV+ (p16 or ISH) 3 2 34 4 43 
HPV- 24 26 8 19 77 
Not Reported 102 150 39 100 391 
% Tested Positive 11.1% 7.1% 81.0% 17.4% 35.8% 
 
Table 6 – Commonly Mutated Genes (TCGA HNSCC) 
 
Cohort (N) YNT (21) OST (46) OT (125) OC (175) OP (76) LH (117) Total HN (493) 
Mean # 
Mutations 
64.6 120.2 93.8 175.4 113.1 224.2 156.7 
TP53 90.5% 73.9% 80.8% 72.6% 28.9% 84.6% 70.8% 
FAT1 14.3% 30.4% 21.6% 32.0% 7.9% 21.4% 23.1% 
CDKN2A 42.9% 21.7% 29.6% 22.9% 6.6% 23.1% 22.1% 
PIK3CA 9.5% 21.7% 17.6% 17.1% 19.7% 22.2% 18.9% 
NOTCH1 19.0% 17.4% 20.0% 20.6% 6.6% 17.1% 17.4% 
NSD1 0.0% 10.9% 5.6% 9.7% 6.6% 27.4% 12.4% 
CASP8 4.8% 8.7% 8.0% 21.1% 2.6% 1.7% 10.3% 
FBXW7 0.0% 4.3% 4.0% 8.6% 3.9% 6.8% 6.3% 
AJUBA 4.8% 2.2% 3.2% 6.3% 2.6% 10.3% 5.9% 
HRAS 4.8% 8.7% 7.2% 10.3% 0.0% 0.9% 5.7% 
HLA-A 0.0% 0.0% 2.4% 7.4% 7.9% 4.3% 5.5% 
NFE2L2 0.0% 8.7% 4.8% 6.3% 2.6% 6.0% 5.3% 
TGFBR2 4.8% 6.5% 4.0% 6.3% 2.6% 2.6% 4.3% 
RB1 0.0% 2.2% 4.0% 1.1% 6.6% 4.3% 3.4% 
CUL3 0.0% 2.2% 0.8% 2.3% 1.3% 6.8% 2.8% 
PTEN 0.0% 2.2% 1.6% 1.7% 3.9% 3.4% 2.4% 
PIK3R1 0.0% 0.0% 0.8% 1.7% 3.9% 0.9% 1.6% 
TRAF3 0.0% 0.0% 0.8% 0.6% 1.3% 1.7% 1.0% 
 
 
  
 
 
 
 
 
 
 
  
Table 7 – Commonly Mutated Genes (Whole Exome) 
YNT OST OT OC OP L/H 
N = 21 N = 46 N = 125 N = 175 N = 76 N = 117 
TP53 90% TP53 74% TP53 81% TP53 73% TTN 36% TP53 85% 
CDKN2A 43% TTN 35% TTN 30% TTN 44% TP53 29% TTN 62% 
MUC16 24% FAT1 30% CDKN2A 30% FAT1 32% PIK3CA 20% CSMD3 41% 
TTN 24% CDKN2A 22% FRG1B 23% CDKN2A 23% MUC16 18% SNHG14 38% 
NOTCH1 19% PIK3CA 22% FAT1 22% CASP8 21% SYNE1 16% SYNE1 30% 
RRN3P2 19% FRG1B 22% NOTCH1 20% NOTCH1 21% HSD17B7P2 16% MUC16 29% 
DYNC1H1 19% CSMD3 20% PIK3CA 18% MUC16 21% LRP1B 16% LRP1B 29% 
PCSK5 14% BAGE2 20% PCLO 17% FRG1B 19% FRG1B 14% NSD1 27% 
FAT1 14% PCLO 20% CSMD3 15% SYNE1 18% 
RP11-
798G7.5 14% KMT2D 26% 
COL1A2 14% AC008103.5 20% BAGE2 15% SNHG14 18% KMT2D 13% USH2A 26% 
RASA1 14% NOTCH1 17% AC008103.5 14% PIK3CA 17% LINC00969 13% FRG1B 26% 
NBPF1 14% USH2A 17% MUC16 14% BAGE2 17% SNHG14 13% BAGE2 26% 
SNHG14 14% DNAH5 15% DNAH5 13% CSMD3 16% TSSC2 13% PCLO 24% 
SZT2 14% CROCCP2 15% SYNE1 13% KMT2D 16% DST 12% CDKN2A 23% 
HUWE1 14% ZFHX4 15% HSD17B7P2 11% FLG 16% CSMD3 12% RYR2 23% 
PMS2CL 14% AHNAK 15% USH2A 10% LRP1B 15% MUC4 12% PKHD1L1 23% 
IKBKB 14% MUC16 13% TSSC2 10% PCLO 14% NIPBL 11% PIK3CA 22% 
PCLO 14% SYNE1 13% LINC00969 10% 
LL22NC03-
80A10.6 14% MACF1 11% LAMA2 22% 
ZMYND11 14% HSD17B7P2 13% LRP1B 10% LINC00969 13% FLG 11% FAT1 21% 
LL22NC03-
80A10.6 14% TSSC2 13% TUBB8P7 10% DNAH5 13% BAGE2 11% FLG 21% 
  
Appendix A 
 
http://seer.cancer.gov/statfacts/html/oralcav.html 
 
